These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 34414366)

  • 1. Therapeutic Advances for Pancreatic Cancer: a Slow and Challenging Feat that Continues to Evolve.
    Blanquicett CJ; Aguirre LE
    Acta Sci Gastron Disord; 2021 Jul; 4(7):50-52. PubMed ID: 34414366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
    Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
    J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma.
    Saeed A; Park R; Al-Jumayli M; Al-Rajabi R; Sun W
    Clin Colorectal Cancer; 2019 Jun; 18(2):81-90. PubMed ID: 30905548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
    Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
    Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Challenges in Cancer Treatment.
    Zugazagoitia J; Guedes C; Ponce S; Ferrer I; Molina-Pinelo S; Paz-Ares L
    Clin Ther; 2016 Jul; 38(7):1551-66. PubMed ID: 27158009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Potential of CAR T Cell Therapy in Pancreatic Cancer.
    Akce M; Zaidi MY; Waller EK; El-Rayes BF; Lesinski GB
    Front Immunol; 2018; 9():2166. PubMed ID: 30319627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Challenge of Developing New Therapies for Childhood Cancers.
    Balis FM
    Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.
    Marofi F; Tahmasebi S; Rahman HS; Kaigorodov D; Markov A; Yumashev AV; Shomali N; Chartrand MS; Pathak Y; Mohammed RN; Jarahian M; Motavalli R; Motavalli Khiavi F
    Stem Cell Res Ther; 2021 Mar; 12(1):217. PubMed ID: 33781320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current controversies and advances in the management of pancreatic adenocarcinoma.
    Zeeshan MS; Ramzan Z
    World J Gastrointest Oncol; 2021 Jun; 13(6):472-494. PubMed ID: 34163568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing the Efficacy of CAR T Cells in the Tumor Microenvironment of Pancreatic Cancer.
    Henze J; Tacke F; Hardt O; Alves F; Al Rawashdeh W
    Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32481570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contemporary Management of Localized Resectable Pancreatic Cancer.
    Kommalapati A; Tella SH; Goyal G; Ma WW; Mahipal A
    Cancers (Basel); 2018 Jan; 10(1):. PubMed ID: 29361690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recent advances and future challenges in cancer immunotherapy].
    Okuyama N; Tamada K; Tamura H
    Rinsho Ketsueki; 2016; 57(11):2388-2395. PubMed ID: 27941290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview.
    Panchal K; Sahoo RK; Gupta U; Chaurasiya A
    Int Immunopharmacol; 2021 Jun; 95():107508. PubMed ID: 33725635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on pancreatic cancer.
    Rocha Lima CM; Centeno B
    Curr Opin Oncol; 2002 Jul; 14(4):424-30. PubMed ID: 12130928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review.
    Boussios S; Seraj E; Zarkavelis G; Petrakis D; Kollas A; Kafantari A; Assi A; Tatsi K; Pavlidis N; Pentheroudakis G
    Crit Rev Oncol Hematol; 2016 Dec; 108():164-174. PubMed ID: 27931835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Mesothelin CAR T cell therapy for malignant mesothelioma.
    Castelletti L; Yeo D; van Zandwijk N; Rasko JEJ
    Biomark Res; 2021 Feb; 9(1):11. PubMed ID: 33588928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Approaches in CAR-T Cell Immunotherapy for Breast Cancer.
    Wang J; Zhou P
    Adv Exp Med Biol; 2017; 1026():371-381. PubMed ID: 29282693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for pancreatic cancer.
    Yoon JH; Jung YJ; Moon SH
    World J Clin Cases; 2021 May; 9(13):2969-2982. PubMed ID: 33969083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic Redirection of T Cells for the Treatment of Pancreatic Cancer.
    Ali AI; Oliver AJ; Samiei T; Chan JD; Kershaw MH; Slaney CY
    Front Oncol; 2019; 9():56. PubMed ID: 30809507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
    Madden DL
    Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.